Lab
Oak Crest Laboratory Services, INC
Oak Crest Laboratory Services, INC was paid $653K by Medicaid between Jan 2018 and Nov 2024, across 23 billing codes. Its largest line is 0241U, Neonatal screening for hereditary disorders, genomic sequence analysis panel — 51% of everything it billed.
33Billing provider infoOAK CREST LABORATORY SERVICES, INC
ALGONQUIN, IL 60102
ALGONQUIN, IL 60102
33aNPI1205876554assigned 06/07/2006
33bProvider typeClinical Medical Laboratory
28Total paid$653K
24GClaims18,940
24DCodes billed23
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Illinois
Rank by total paid#82 of 235
Median peer was paid$123K
This provider vs. median5.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,675 | $10K | |
| 2019 | 1,281 | $5K | |
| 2021 | 587 | $2K | |
| 2022 | 1,270 | $36K | |
| 2023 | 7,645 | $166K | |
| 2024incomplete | 5,482 | $433K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 51% | 3,026 | 735 | $334K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 18% | 1,898 | 709 | $115K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 12% | 2,215 | 629 | $77K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 5.6% | 1,927 | 753 | $37K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 4.2% | 1,359 | 660 | $28K |
| 87631 | 3.7% | 309 | 106 | $24K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.0% | 2,960 | 1,743 | $13K |
| 80053 | Comprehensive metabolic panel | 1.6% | 1,313 | 727 | $11K |
| 85610 | <1% | 1,814 | 841 | $4K | |
| 83735 | <1% | 511 | 242 | $3K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 447 | 255 | $3K |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 389 | 169 | $984.82 |
11 more codes
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 15 | $685.77 |
| 36415 | Collection of venous blood by venipuncture | <1% | 276 | $662.34 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 13 | $595.40 |
| 83615 | <1% | 117 | $522.52 | |
| 86140 | <1% | 109 | $406.60 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 62 | $284.20 |
| 85652 | <1% | 107 | $228.23 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 17 | $206.65 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 14 | $110.46 |
| 84100 | <1% | 24 | $92.22 | |
| 80061 | Lipid panel | <1% | 18 | $74.55 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGAMBINO, RUSSELL (PRESIDENT)